Call for abstracts deadline: September 8, 2010
Featured Conference Topics:
- Optimal Clinical Trial Designs
- Diabetes Mellitus Regulatory Guidances
- Post-marketing Assessments
- Preclinical Testing to Evaluate CV Risk and Mechanistic Considerations
- Biomarkers, Pharmacogenomics, and Collaborative Efforts
Featured FDA Speakers:
- Dr. Robert J. Temple, Deputy Center Director for Clinical Science, CDER
- Dr. Mary Parks, Director, Division of Metabolism and Endocrinology Products, Office of Drug Evaluation II, Office of New Drugs, CDER
- Dr. Norman Stockbridge, Director, Division of Cardiovascular and Renal Products, Office of Drug Evaluation I, Office of New Drugs, CDER
- Dr. Ilan Irony, Clinical Team Leader, Division of Metabolism and Endocrinology Products, Office of New Drugs, CDER
- Dr. Hylton V. Joffe, Lead Medical Officer, Diabetes Drug Group I, Division of Metabolism and Endocrinology Products, Office of New Drugs, CDER
- Dr. J. Todd Sahlroot, Deputy Director and Team Leader, Office of Translational Sciences, Office of Biostatistics, CDER